Overview (Program Summary)
Same same, but different. Using case studies we will discuss the FDA’s position on interchangeable biosimilars and what it means to be “highly similar” and have “no clinically meaningful differences”.
Speakers
David Rosen, Partner, Foley & Lardner, LLP
Justin Underwood, Associate General Counsel, Evolus